Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles

Drug Development and Industrial Pharmacy

Volumn 42, Issue 8, 2016, Pages 1325-1333

  Gu, Lingling ^a,b   Zhao, Yuan ^a,b   Lu, Weigen ^a,b  

^a Shanghai Institute of Pharmaceutical Industry   (China)

^b CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

Author keywords

Asiatic acid tromethamine salt; Enhanced oral bioavailability; Modified solvent injection; Stable SLN

Indexed keywords

ASIATIC ACID; ASIATIC ACID TROMETHAMINE SALT; GLYCERIN MONOSTEARATE; GLYCEROL; POLOXAMER; SOLID LIPID NANOPARTICLE; SOLVENT; TROMETAMOL; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; NANOPARTICLE; PENTACYCLIC TRITERPENE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; COACERVATION; CONTROLLED STUDY; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; GEL FILTRATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PROCESS OPTIMIZATION; RAT; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; LIPIDS; MALE; NANOPARTICLES; PARTICLE SIZE; PENTACYCLIC TRITERPENES; RATS; RATS, SPRAGUE-DAWLEY; TROMETHAMINE;

EID: 85009754390     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1135934     Document Type: Article

References (38)

1. Zhang J, Ai L, Lv T, et al. Asiatic acid, a triterpene, inhibits cell proliferation through regulating the expression of focal adhesion kinase in multiple myeloma cells. Oncol Lett 2013;6:1762-6.
2. Park BC, Bosire KO, Lee ES, et al. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. Cancer Lett 2005;218:81-90.
3. Chan CY, Mong MC, Liu WH, et al. Three pentacyclic triterpenes protect H9c2 cardiomyoblast cells against high-glucose-induced injury. Free Radic Res 2014;48:402-11.
4. Li ZW, Piao CD, Sun HH, et al. Asiatic acid inhibits adipogenic differentiation of bone marrow stromal cells. Cell Biochem Biophys 2014;68:437-42.
5. Pakdeechote P, Bunbupha S, Kukongviriyapan U, et al. Asiatic acid alleviates hemodynamic and metabolic alterations via restoring eNOS/iNOS expression, oxidative stress, and inflammation in diet-induced metabolic syndrome rats. Nutrients 2014;6:355-70.
6. Ramachandran V, Saravanan R, Senthilraja P. Antidiabetic and antihyperlipidemic activity of asiatic acid in diabetic rats, role of HMG CoA: in vivo and in silico approaches. Phytomedicine 2014;21:225-32.
7. Yan SL, Yang HT, Lee YJ, et al. Asiatic acid ameliorates hepatic lipid accumulation and insulin resistance in mice consuming a high-fat diet. J Agric Food Chem 2014;62:4625-31.
8. Yuan Y, Zhang H, Sun F, et al. Biopharmaceutical and pharmacokinetic characterization of asiatic acid in Centella asiatica as determined by a sensitive and robust HPLC-MS method. J Ethnopharmacol 2015;163:31-8.
9. Zhao YL, Hai W, Zheng HH, et al. Enhancing water-solubility of poorly soluble drug, asiatic acid with hydroxypropyl- b-cyclodextrin. Dig J Nanomater Bios 2010;5:419-25.
10. Zhang YW, Yin LN, Liang ZH, et al. Microstructure of asiatic acid lipid nanoparticles and its effect on intestinal absorption kinetics. Chin J New Drugs 2014;23:2284-97.
11. Rezonja R, Knez L, Cufer T, et al. Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions. Radiol Oncol 2013;47:1-13.
12. Khan J, Alexander A. Ajazuddin, et al. Luteolin-phospholipid complex: preparation, characterization and biological evaluation. J Pharm Pharmacol 2014;66:1451-62.
13. Zhang Z, Chen Y, Deng J, et al. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO: preparation, characterization and in vivo studies. Int J Pharm 2014;465:306-16.
14. Yao Y, Xie Y, Hong C, et al. Development of a myricetin/ hydroxypropyl-b-cyclodextrin inclusion complex: preparation, characterization, and evaluation. Carbohydr Polym 2014;110:329-37.
15. Chen Y, Li G, Huang JG, et al. Comparison of self-microemulsifying drug delivery system versus solid dispersion technology used in the improvement of dissolution rate and bioavailability of vinpocetine. Yao Xue Xue Bao 2009;44:658-66.
16. Yang KY, Hwang du H, Yousaf AM, et al. Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation. Int J Nanomedicine 2013;8:3333-43.
17. Müller R, Mehnert W, Lucks J-S, et al. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995;41:62-9.
18. Freitas C, Muller RH. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul 1999;16:59-71.
19. Zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55.
20. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96.
21. Muller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317:82-9.
22. Tran TH, Ramasamy T, Truong DH, et al. Development of vorinostat- loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res 2014;31:1978-88.
23. Hosny KM, Aljaeid BM. Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. Expert Opin Drug Deliv 2014;11:1015-22.
24. Tran TH, Ramasamy T, Cho HJ, et al. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotechnol 2014;14:4820-31.
25. Bummer PM. Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst 2004;21:1-20.
26. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405.
27. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011;8:1407-24.
28. Liu CH, Wu CT, Fang JY. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm 2010;36:751-61.
29. Box GEP, Wilson KB. On the experimental attainment of optimum conditions. J Roy Stat Soc B 1951;13:1-45.
30. Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics 1960;2:455-75.
31. Bezerra MA, Santelli RE, Oliveira EP, et al. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta 2008;76:965-77.
32. Muller RH, Heinemann S. Fat emulsions for parenteral nutrition. I: evaluation of microscopic and laser light scattering methods for the determination of the physical stability. Clin Nutr 1992;11:223-36.
33. Muller RH, Heinemann S. Fat emulsions for parenteral nutrition II: characterisation and physical long-term stability of lipofundin MCT LCT. Clin Nutr 1993;12:298-309.
34. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62-76.
35. Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55:125-31.
36. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
37. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131-55.
38. Yao M, Xiao H, McClements DJ. Delivery of lipophilic bioactives: assembly, disassembly, and reassembly of lipid nanoparticles. Annu Rev Food Sci Technol 2014;5:53-81.